Pharmaceutical giant Eli Lilly has confirmed a definitive timeline for the introduction of its redesigned Mounjaro KwikPens in the United Kingdom, effectively terminating the controversial practice known as the 'golden dose'. The updated injection devices are scheduled to become available from April 2026, marking a significant shift in how the weight-loss medication is administered.
End of an Era for Cost-Cutting Hack
The current 3ml pre-filled pens are engineered to deliver four precise weekly doses of Mounjaro. However, a small residual amount of medication frequently remains after the fourth injection. Some resourceful patients have exploited this leftover liquid by extracting it with a syringe to administer an unofficial fifth dose, a method colloquially dubbed the 'golden dose'.
The newly modified KwikPen has been specifically redesigned to minimise this residual medication, thereby preventing users from obtaining any extra doses. An Eli Lilly spokesperson clarified the device's purpose, stating it 'continues to contain four fixed doses of medicine, along with a small additional amount to allow users to prime the pen before injection.' They emphasised that 'the KwikPen should be disposed of after four doses, and the small amount of residual medicine should not be used.'
Design Changes and Market Transition
While functionally identical to its predecessor, the revamped pen incorporates several key visual and structural modifications. The plunger now rests further down the cartridge when unused, and a new internal component extends its length. After the fourth and final dose, the plunger will sit conspicuously near the pen's end, providing a clear visual indicator that the device is empty and should be discarded.
Existing stocks of the original KwikPen will continue to be supplied until depletion, ensuring a transitional period where both versions coexist in the market. This phased approach has already sparked concern among users, with one commenting online about the 'random chance' of receiving old or new pens making stockpiling a risky strategy.
Safety Warnings Amid Soaring Costs
Health authorities have consistently warned against the 'golden dose' practice. Dr Alison Cave, chief safety officer of the Medicines and Healthcare products Regulatory Agency (MHRA), stressed that 'failure to adhere with these guidelines, such as tampering with pre–dosed injection pens, could harm your health or cause personal injury.'
Professor Penny Ward, a pharmaceutical expert at King's College London, elaborated on the dangers, noting that extracting leftover liquid risks serious infection. 'The pens are sterile when dispensed, but once they've been used, they're no longer sterile,' she explained. 'That means using leftover liquid to inject into the skin could introduce harmful bacteria,' potentially leading to abscesses or even life-threatening sepsis.
Financial Pressure Driving Risky Behaviour
The redesign coincides with substantial price increases for Mounjaro in the private market. From September 1, 2025, Eli Lilly raised the UK private wholesale price by up to 170 percent. For instance, the cost for the highest 15mg dose escalated from approximately £122 to £330 per month. Currently, Pharmacy2U lists this pen at £299.99, a significant jump from its previous £180 price tag.
This steep hike triggered what was described as 'Covid-like panic buying' when smaller pens were first announced in September 2025, with users boasting online about purchasing months' worth of stock to avoid the new prices. The financial incentive to extend pen usage was considerable; by obtaining a fifth dose from each pen, regular users could save around £615 annually.
Online forums have been rife with discussions about the 'golden dose', with users sharing extraction tips to make pens last longer. Reactions to the redesign have been fiercely critical, with some labelling Eli Lilly's decision a 'kick in the teeth' and vowing to continue attempting to extract any leftover medication. 'Maybe half a dose left over so combining two pens with leftover for a full dose. The new golden 9th,' one user speculated defiantly.
Broader Context of Mounjaro Access
Mounjaro, which can help patients shed up to a fifth of their body weight, is officially recommended on the NHS only for patients with a BMI over 40 who also have weight-related health conditions like type 2 diabetes or high blood pressure. However, tens of thousands are believed to be accessing it privately.
A recent analysis highlighted a 'postcode lottery' in NHS provision, with less than half of England's commissioning bodies having started prescribing the drug since its phased rollout began in June 2025. This limited access occurs against a backdrop where weight-related illness costs the UK economy £74 billion annually, and two in three Britons are classified as overweight or obese.
The introduction of the modified KwikPen from April 2026 represents a pivotal moment, aiming to enhance patient safety by eliminating a hazardous practice, even as it removes a cost-saving loophole that many had come to rely upon amidst rising healthcare expenses.
